Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Receivables (2016 - 2025)

Collegium Pharmaceutical has reported Receivables over the past 10 years, most recently at $231.2 million for Q4 2025.

  • Quarterly results put Receivables at $231.2 million for Q4 2025, down 8.82% from a year ago — trailing twelve months through Dec 2025 was $231.2 million (down 8.82% YoY), and the annual figure for FY2025 was $231.2 million, down 8.82%.
  • Receivables for Q4 2025 was $231.2 million at Collegium Pharmaceutical, down from $233.9 million in the prior quarter.
  • Over the last five years, Receivables for COLL hit a ceiling of $253.5 million in Q4 2024 and a floor of $90.1 million in Q2 2021.
  • Median Receivables over the past 5 years was $182.5 million (2022), compared with a mean of $181.8 million.
  • Biggest five-year swings in Receivables: skyrocketed 119.21% in 2022 and later fell 15.2% in 2023.
  • Collegium Pharmaceutical's Receivables stood at $105.8 million in 2021, then soared by 73.01% to $183.1 million in 2022, then fell by 1.96% to $179.5 million in 2023, then soared by 41.23% to $253.5 million in 2024, then dropped by 8.82% to $231.2 million in 2025.
  • The last three reported values for Receivables were $231.2 million (Q4 2025), $233.9 million (Q3 2025), and $213.0 million (Q2 2025) per Business Quant data.